-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Old Xue Changsheng side of the stock rose, bankruptcy before the first few spring? When Junshi Bio went up 172% on the day it went on the market, it was like an upgraded version of The Vantai Creatures.
the latter crazy pull 26 one-word board up and down, let all walks of life marvel at excellence.
and Huluwa Pharmaceuticals since the listing has also been achieving a high, even the sale of NMN health care products JinDawei has received four consecutive ups and downs.
search this health care product in Tmall online shop, priced at 1699 yuan, but not the money can buy, because it will sell out.
is also in Tmall's online store, where another company is going through a bankruptcy auction.
Changchun Changsheng went bankrupt, leaving a number of industries for auction.
the most remarkable should be in the research project, shingles vaccine, 156790217.32 yuan.
there is zero whole, the fare increase is 700,000 one.
even patent for vaccine freeze-dried protection agent, freeze-dried chickenpox anti-venom vaccine and preparation method, has been auctioned for thousands of dollars.
a lot of raw materials also cashed out successfully, cattle serum to 956865 yuan to start, bidding dozens of times finally sold 1532865 yuan.
failed, a large number of chemical reagents, despite 1974 onlookers, but still can not stop the March 17 thin shooting.
bankruptcy auction, as the last way to raise money, has not been so good, again auction has become a helpless action.
long-term equity investment in Jiangsu Huakang Pharmaceuticals shares is to be auctioned again at the end of the month.
deserve syds of the long-lived shingles vaccine relative to this non-physical stake. after
, after all, there is only one application for the Drug Assistant APP, which comes from glaxoSmithKline Biological SA's recombinant shingles vaccine, imported.
this is one of the country's first batch of 48 overseas listed "clinically urgently needed new drugs", and is currently the only domestic market recombinant shingles vaccine.
if Changchun Changsheng this can be shipped to the market, is undoubtedly competitive. after
after all, the pain caused by shingles is very unbearable, will lead to burns, electric shocks, knife-like pain, acute pain than the pain of childbirth is even stronger, serious can lead to mental disorders and depression.
and with the increase of age and disease, drug effects on the human body, the incidence of a significant upward trend, patients over 50 years of age, the quality of life will be significantly reduced.
and the incidence rate in China is between three and nine thousandths.
so changchun Changsheng this step of chess is very correct, but not timely enough.
if it were not for the middle pause, it would be unknown that debt would be repaid now.
returnto head to say Junshi biological, the current market value of Junshi biological has exceeded 100 billion.
is almost a quarter of the company's leading biopharmaceutical leader Hengrui Pharmaceuticals, but its 2019 revenues are only 775 million.
low earnings state listing, coupled with soaring gains, can not avoid the eyes of capital.
relative to The until the Wantai biological diversification of products, from vaccines to equipment to diagnostic reagents production line, Junshi biological only a PD-1 anti-cancer drug, Trepri monoanti-resisting to support the overall situation, no doubt very difficult.
after all, now PD-1 is everyone's eyes, are chasing, relying on a trick to eat all over the world, may not be able to maintain this advantage in the long term.
in addition, The use of Tripri monotoma therapy is melanoma, which is not large in the domestic market.
The top five most common cancers in 2019 are breast cancer, lung cancer, prostate cancer, colorectal cancer and melanoma, according to the U.S. Cancer Statistics report.
but melanoma has a human difference, the highest incidence rate in China is lung cancer, stomach cancer, colorectal cancer, liver cancer and breast cancer.
so from the point of view of drug sales, the domestic market can only rely on a large population base to offset the low incidence.
like selling sugary sweet bread in the north, buying fewer people.
of course, companies are also under going on to see if they can add new indications to supplement profits.
selection is very important to the market, like NMN health care products, earn money is rich people.
for the rich, as long as it is good for longer life, it is rigid demand.
and NMN belongs to the long-term supplement, this high value, stable source of the road, is definitely a Kangzhuang Avenue.
and for me, to earn money and health in the same dimension, really give me a few bottles of NMN as a wage, immediately have to kneel.
so Junshi biological must expand new business, in order to be able to afford this hundreds of billions of dollars worth.
after all, foreign PD-1 is a competitive big indication, a wide range of markets, can self-promote "save one more person", but selling more than one is the way to survive.
the current frenzied stock market, may overdraft the strength of the enterprise development.
this is very need to pay attention to, in case the enterprise really to use money, the stock market to cut off, even if there is no operating problems, I am afraid will be like a thousand yam machine like face de-listing.
need to be reminded that hot money only heat, will not bring a guaranteed warmth.
thousands of mountain birds fly away, thousands of people disappear.
is not a skill, greed is difficult to eliminate.
reference material: "China's strip herpes treatment guide" (draft) "domestic PD-1 single anti-commercialization start, the first echelon cast moat", Ping An Securities "from PD-1 single anti-anti-innovative drugs to see China's innovative drug break-out road", Guangdong Kai Securities statement: this article was written by the author, the point of view only on behalf of the author himself, not on behalf of the Amida industry research position.
this public number is for the sole purpose of transmitting more information.
.